CRGX vs. MESO, RGNX, IMTX, BCRX, HLVX, PRME, NVAX, KYTX, EXAI, and CABA
Should you be buying CARGO Therapeutics stock or one of its competitors? The main competitors of CARGO Therapeutics include Mesoblast (MESO), REGENXBIO (RGNX), Immatics (IMTX), BioCryst Pharmaceuticals (BCRX), HilleVax (HLVX), Prime Medicine (PRME), Novavax (NVAX), Kyverna Therapeutics (KYTX), Exscientia (EXAI), and Cabaletta Bio (CABA). These companies are all part of the "biological products, except diagnostic" industry.
CARGO Therapeutics (NASDAQ:CRGX) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
CARGO Therapeutics presently has a consensus target price of $29.67, suggesting a potential upside of 56.14%. Mesoblast has a consensus target price of $13.67, suggesting a potential upside of 90.61%. Given Mesoblast's higher probable upside, analysts clearly believe Mesoblast is more favorable than CARGO Therapeutics.
Mesoblast received 398 more outperform votes than CARGO Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CARGO Therapeutics an outperform vote while only 70.45% of users gave Mesoblast an outperform vote.
In the previous week, Mesoblast had 1 more articles in the media than CARGO Therapeutics. MarketBeat recorded 3 mentions for Mesoblast and 2 mentions for CARGO Therapeutics. CARGO Therapeutics' average media sentiment score of 1.54 beat Mesoblast's score of 0.33 indicating that CARGO Therapeutics is being referred to more favorably in the media.
93.2% of CARGO Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 1.4% of CARGO Therapeutics shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Mesoblast has higher revenue and earnings than CARGO Therapeutics.
Summary
Mesoblast beats CARGO Therapeutics on 6 of the 11 factors compared between the two stocks.
Get CARGO Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CARGO Therapeutics Competitors List
Related Companies and Tools
